Compare TACT & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TACT | SCYX |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.2M | 32.6M |
| IPO Year | 1996 | 2014 |
| Metric | TACT | SCYX |
|---|---|---|
| Price | $3.48 | $0.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $5.00 | $3.00 |
| AVG Volume (30 Days) | 41.5K | ★ 328.6K |
| Earning Date | 06-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.88 | 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $257,000.00 |
| Revenue This Year | $21.67 | $90.24 |
| Revenue Next Year | $7.63 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.06 | $0.57 |
| 52 Week High | $5.70 | $1.29 |
| Indicator | TACT | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 44.89 | 62.21 |
| Support Level | N/A | $0.69 |
| Resistance Level | $3.87 | $0.88 |
| Average True Range (ATR) | 0.22 | 0.06 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 50.72 | 72.97 |
Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.